Noting that it launched against “perhaps the most consequential backdrop imaginable for the overall Biotech industry,” today’s article examines the recent performance of the Nasdaq Junior Biotechnology Index (NBIJR) which, as its name suggests, focuses on smaller biotech companies – and thus “offers a less concentrated, but ultimately more speculative, way to track companies driving the future of the biotech industry.” For a look at the performance of the NBIJR since its April 30th launch, its current composition, and drivers of future performance, CLICK HERE.